The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Open accessAbstract
BACKGROUND: BRAF V600 mutations occur in various nonmelanoma cancers. We undertook a histology-independent phase 2 "basket" study of vemurafenib in BRAF V600 mutation-positive nonmelanoma cancers. METHODS: We enrolled patients in six prespecified cancer cohorts; patients with all other tumor types were enrolled in a seventh cohort. A total of 122 patients with BRAF V600 mutation-positive cancer were treated, including 27 patients with colorectal cancer who received vemurafenib and cetuximab. The primary end point was the response rate; secondary end points included progression-free and overall survival. RESULTS: In the cohort with non-small-cell lung cancer, the response rate was 42% (95% confidence interval [CI], 20 to 67) and median progression-free survival was 7.3 months (95% CI, 3.5 to 10.8). In the cohort with Erdheim-Chester disease or Langerhans'-cell histiocytosis, the response rate was 43% (95% CI, 18 to 71); the median treatment duration was 5.9 months (range, 0.6 to 18.6), and no patients had disease progression during therapy. There were anecdotal responses among patients with pleomorphic xanthoastrocytoma, anaplastic thyroid cancer, cholangiocarcinoma, salivary-duct cancer, ovarian cancer, and clear-cell sarcoma and among patients with colorectal cancer who received vemurafenib and cetuximab. Safety was similar to that in prior studies of vemurafenib for melanoma. CONCLUSIONS: BRAF V600 appears to be a targetable oncogene in some, but not all, nonmelanoma cancers. Preliminary vemurafenib activity was observed in non-small-cell lung cancer and in Erdheim-Chester disease and Langerhans'-cell histiocytosis. The histologic context is an important determinant of response in BRAF V600-mutated cancers. (Funded by F. Hoffmann-La Roche/Genentech; ClinicalTrials.gov number, NCT01524978.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, in BRAFV600 colorectal cancer, targeting EGFR—the RTK thought to be the primary driver of feedback reactivation from preclinical studies—in combination with BRAF inhibition, has led to an improvement in clinical efficacy (34–39).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAF inhibitors have proven ineffective as single agents due to adaptive feedback re-activation of the MAPK and other signaling pathways [5–13, 38].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“BRAF inhibitor monotherapy is a promising treatment of many cancers, including melanoma and NSCLC; however, BRAF inhibitor efficacy in colorectal cancer patients with BRAF V600E mutations is limited (21).”
From Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRASG12DInhibitor, in Colorectal Cancer Treatment (2023) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“In contrast with other BRAFV600E tumors (i.e. melanoma), BRAFV600E-targeted therapy (like vemurafenib) has proven largely ineffective in CRC, with response rates <5% as single agents [5, 6].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [6]
In the citing paper
“However, in another clinical study, CRC patients did not benefit from vemurafenib monotherapy and/or cetuximab [161].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [161]
In the citing paper
“However, a multicentric clinical study containing 27 CRC patients showed that vemurafenib alone or with cetuximab did not benefit CRC patients [99].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citationMutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
The cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Self-citationThe Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
Flagged first, then by citations
Research works printed but not linked: 1
- Kimura ET, 2003, Cancer Res, 63, 1454
Cited by
Sorted by citations
Items 801–900 of 1,002
Recent Advances in Targeted Therapies for Advanced Gastrointestinal Malignancies
Huynh, J. C., Schwab, E., Ji, J., Kim, E. J.-H., Joseph, A., Hendifar, A. E., Cho, M. T., & Gong, J. (2020) · Cancers · doi:10.3390/cancers12051168 · Cited by 23
Cortiana, V., Abbas, R. H., Chorya, H. P., Gambill, J. L., Mahendru, D., Park, C. H., & Leyfman, Y. (2024) · Cancers · doi:10.3390/cancers16132329 · Cited by 19
Systemic treatments in recurrent or metastatic salivary gland cancer: a systematic review
Prost, D. M., Iseas, S., Gatineau, M., Adam, J., Cavalieri, S., Bergamini, C., Licitra, L., & Raymond, É. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103722 · Cited by 19
Progress of Immune Checkpoint Inhibitors Therapy for pMMR/MSS Metastatic Colorectal Cancer
Qu, F., Wu, S., & Yu, W. (2024) · OncoTargets and Therapy · doi:10.2147/ott.s500281 · Cited by 20
Shimada, Y., Muneoka, Y., Nagahashi, M., Ichikawa, H., Tajima, Y., Hirose, Y., Ando, T., Nakano, M., Sakata, J., Kameyama, H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-39328-6 · Cited by 19
Run, L., Wang, L., Nong, X., Li, N., Huang, X., & Xiao, Y. (2020) · Endocrine · doi:10.1007/s12020-020-02417-y · Cited by 19
Cholangiocarcinoma: investigations into pathway-targeted therapies
Ntanasis‐Stathopoulos, I., Tsilimigras, D. I., Gavriatopoulou, M., Schizas, D., & Pawlik, T. M. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1807333 · Cited by 19
Precision approaches for cholangiocarcinoma: progress in clinical trials and beyond
Usón, P. L. S., & Borad, M. J. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2017882 · Cited by 19
Evolution of Treatment in Advanced Cholangiocarcinoma: Old and New towards Precision Oncology
Capuozzo, M., Santorsola, M., Landi, L., Granata, V., Perri, F., Celotto, V., Gualillo, O., Nasti, G., & Ottaiano, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315124 · Cited by 19
Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer
Leone, G. M., Candido, S., Lavoro, A., Vivarelli, S., Gattuso, G., Călina, D. C., Libra, M., & Falzone, L. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041252 · Cited by 21
Geerlinks, A. V., & Abla, O. (2023) · Pediatric Drugs · doi:10.1007/s40272-023-00569-8 · Cited by 20
Blay, J., Cropet, C., Mansard, S., Loriot, Y., de la Fouchardière, C., Haroche, J., Topart, D., Tougeron, D., You, B., Italiano, A., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.102038 · Cited by 19
Self-citationBRAF inhibitors in BRAF-V600 mutated primary neuroepithelial brain tumors
Preusser, M., Bieńkowski, M., & Birner, P. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1110143 · Cited by 19
Wu, Z., Huang, M., Gong, Y., Chen, L., & Guo, W. (2018) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmy018 · Cited by 19
Sequencing Therapy for Genetically Defined Subgroups of Non–Small Cell Lung Cancer
Yu, H. A., Planchard, D., & Lovly, C. M. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_201331 · Cited by 20
Stewart, A., Coker, E. A., Pölsterl, S., Georgiou, A., Minchom, A. R., Carreira, S., Cunningham, D., O'Brien, M. E. R., Raynaud, F. I., Bono, J. S. D., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0727 · Cited by 20
Kurzrock, R., Gurski, L. A., Carlson, R. W., Ettinger, D. S., Horwitz, S. M., Kumar, S. K., Million, L., von Mehren, M., & Benson, A. B. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz232 · Cited by 19
Moreira, A., Masliah‐Planchon, J., Callens, C., Vacher, S., Lecerf, C., Frélaut, M., Borcoman, É., Torossian, N., Ricci, F., Hescot, S., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.09.001 · Cited by 19
Basket trials: From tumour gnostic to tumour agnostic drug development
Dittrich, C. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102082 · Cited by 18
Murphy, P. J., Claxton, L., Hodgson, R. M., Glynn, D., Beresford, L., Walton, M., Llewellyn, A., Palmer, S., & Dias, S. (2021) · Medical Decision Making · doi:10.1177/0272989x20980327 · Cited by 19
Advanced Bile Duct Cancers: A Focused Review on Current and Emerging Systemic Treatments
Cowzer, D., & Harding, J. J. (2022) · Cancers · doi:10.3390/cancers14071800 · Cited by 19
Thomas, A. A., Tucker, S., Nelson, C., Nickerson, J. P., Durham, S. R., & Homans, A. C. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27465 · Cited by 19
Carlo, M. I., Khan, N. A., Zehir, A., Patil, S., Ged, Y. M. A., Redzematovic, A., Coskey, D. T., Hyman, D. M., Ladanyi, M., Chen, Y., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00372 · Cited by 18
Self-citationDeveloping Anticancer Drugs in Orphan Molecular Entities — A Paradigm under Construction
André, F. (2018) · New England Journal of Medicine · doi:10.1056/nejme1716821 · Cited by 19
Anaplastic thyroid cancer: Genetic roles, targeted therapy, and immunotherapy
Zou, Z., & Zhong, L. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101403 · Cited by 19
Napolitano, S., Ciardiello, D., Cioli, E., Martinelli, E., Troiani, T., Zampino, M. G., Fazio, N., Vita, F. D., Ciardiello, F., & Martini, G. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102905 · Cited by 19
Rebello, R. J., Posner, A., Dong, R., Prall, O. W. J., Sivakumaran, T., Mitchell, C. B., Flynn, A., Caneborg, A., Mitchell, C., Kanwal, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59661-x · Cited by 19
Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context
Le, A., Alzghari, S. K., Jean, G. W., & La-Beck, N. M. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s104343 · Cited by 18
VCAM-1 Upregulation Contributes to Insensitivity of Vemurafenib in BRAF-Mutant Thyroid Cancer
Chen, S., Su, X., Jiang, X., Zhang, T., Min, I. M., Ding, Y., Wang, X., Mao, Z., Cao, J., Teng, X., et al. (2020) · Translational Oncology · doi:10.1016/j.tranon.2019.10.007 · Cited by 18
Li, H., Yang, K., & Wang, Y. (2021) · Gastroenterology report · doi:10.1093/gastro/goab031 · Cited by 18
Rocha, M. L., Schmid, K. W., & Czapiewski, P. (2021) · Współczesna Onkologia · doi:10.5114/wo.2021.110052 · Cited by 18
Targeting RAF dimers in RAS mutant tumors: From biology to clinic
Yin, H., Tang, Q., Xia, H., & Bi, F. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.02.018 · Cited by 18
Silkin, S. V., Startsev, S. S., Krasnova, M. E., Раскин, Г. А., Mitiushkina, N. V., Iyevleva, A. G., Соколенко, А. П., & Имянитов, Е. Н. (2015) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-015-9792-2 · Cited by 18
Response to Targeted Therapy inBRAFMutant Anaplastic Thyroid Cancer
Agarwal, R., Wang, J., Wilson, K. M. O., Barrett, W. L., & Morris, J. C. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0130 · Cited by 18
Targeted Therapies in Non-small-Cell Lung Cancer
Hill, A., Gupta, R. V., Zhao, D., Vankina, R., Amanam, I. U., & Salgia, R. (2019) · Cancer treatment and research · doi:10.1007/978-3-030-16391-4_1 · Cited by 18
Deng, L., Gao, G., Deng, H.-B., Wang, F., Wang, Z., & Yu, Y. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03001-2 · Cited by 18
TRK fusion positive cancers: From first clinical data of a TRK inhibitor to future directions
Roviello, G., D’Angelo, A., Sciortino, M., Mini, E., Nobili, S., Logu, F. D., & Massi, D. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103011 · Cited by 19
Statistical design considerations for trials that study multiple indications
Kaizer, A. M., Koopmeiners, J. S., Chen, N., & Hobbs, B. P. (2020) · Statistical Methods in Medical Research · doi:10.1177/0962280220975187 · Cited by 18
Ziogas, I. A., Kakos, C. D., Wu, W. K., Montenovo, M. I., Matsuoka, L. K., Zarnegar‐Lumley, S., & Alexopoulos, S. P. (2021) · Liver Transplantation · doi:10.1002/lt.25995 · Cited by 18
Identification of Potential BRAF Inhibitor Joint Therapy Targets in PTC based on WGCAN and DCGA
Han, Y., Yu, X., Yin, Y., Lv, Z., Jia, C., Liao, Y., Sun, H., Liu, T., Cong, L., Fei, Z., et al. (2021) · Journal of Cancer · doi:10.7150/jca.51551 · Cited by 18
Pircher, M., Winder, T., & Trojan, A. (2021) · Case Reports in Oncology · doi:10.1159/000513905 · Cited by 18
Spectrum ofBRAFMutations and Gene Rearrangements in Ovarian Serous Carcinoma
Chui, M. H., Chang, J. C., Zhang, Y., Zehir, A., Schram, A. M., Konner, J. A., Drilon, A. E. D. C., Paula, A. D. C., Weigelt, B., & Grisham, R. N. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00055 · Cited by 19
The Evolution of BRAF Activation in Non-Small-Cell Lung Cancer
Zhang, L., Zheng, L., Yang, Q., & Sun, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.882940 · Cited by 19
Lyu, J., Zhou, T., Yuan, S., Guo, W., & Ji, Y. (2023) · Journal of the Royal Statistical Society Series C (Applied Statistics) · doi:10.1093/jrsssc/qlad025 · Cited by 18
High-throughput drug library screening identifies colchicine as a thyroid cancer inhibitor
Zhang, L., Yang, Z., Granieri, L., Pasculescu, A., Datti, A., Asa, S. L., Xu, Z., & Ezzat, S. (2016) · Oncotarget · doi:10.18632/oncotarget.7890 · Cited by 16
Beyond KRAS: Practical Molecular Targets in Pancreatic Adenocarcinoma
Grinshpun, A., Zarbiv, Y., Roszik, J., Subbiah, V., & Hubert, A. (2019) · Case Reports in Oncology · doi:10.1159/000496018 · Cited by 18
Self-citationSubbiah, V., Dumbrava, E. I., Jiang, Y., Thein, K. Z., Naing, A., Hong, D. S., Fu, S., Piha-Paul, S. A., Tsimberidou, A. M., Jankú, F., et al. (2020) · Experimental Hematology and Oncology · doi:10.1186/s40164-020-00159-1 · Cited by 19
Self-citationDelivering on the promise of precision cancer medicine
Berger, M. F., & Allen, E. M. V. (2016) · Genome Medicine · doi:10.1186/s13073-016-0373-1 · Cited by 18
Giopanou, I., & Pintzas, A. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.102859 · Cited by 17
Cabanillas, M. E., Busaidy, N. L., Khan, S. A., Gunn, G. B., Dadu, R., Rao, S. N., & Waguespack, S. G. (2016) · International Journal of Endocrine Oncology · doi:10.2217/ije-2016-0007 · Cited by 17
Chen, J., Xu, C., Lv, J., Lu, W., Zhang, Y., Wang, D., & Song, Y. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-566 · Cited by 18
Lauinger, M., Christen, D., Klar, R. F. U., Roubaty, C., Heilig, C. E., Stumpe, M., Knox, J. J., Radulovich, N., Tamblyn, L., Xie, I. Y., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade7486 · Cited by 17
RAF and MEK Inhibitors in Non-Small Cell Lung Cancer
Adamopoulos, C., Papavassiliou, K. A., Poulikakos, P. I., & Papavassiliou, A. G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094633 · Cited by 18
Let's Not Put All Our Eggs in One Basket
Hunter, D. J., & D’Agostino, R. B. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1508144 · Cited by 17
Park, H. S., Lim, S. M., Kim, S., Kim, S., Kim, H. R., Kwack, K., Lee, M. G., Kim, J.-H., & Moon, Y. W. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154133 · Cited by 17
Halpenny, D. F., Plodkowski, A. J., Riely, G. J., Zheng, J., Litvak, A. M., Moscowitz, C., & Ginsberg, M. S. (2016) · Clinical Imaging · doi:10.1016/j.clinimag.2016.11.015 · Cited by 17
Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas
Gouravan, S., Meza‐Zepeda, L. A., Myklebost, O., Stratford, E. W., & Munthe, E. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19040969 · Cited by 18
Beg, S., Bareja, R., Ohara, K., Eng, K., Wilkes, D. C., Pisapia, D. J., Zoughbi, W. A., Kudman, S., Zhang, W., Rao, R. A., et al. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100944 · Cited by 17
Baiocchi, L., Sato, K., Ekser, B., Kennedy, L. L., Francis, H., Ceci, L., Lenci, I., Alvaro, D., Franchitto, A., Onori, P., et al. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1854725 · Cited by 17
Giordano, G., Parcesepe, P., Bruno, G., Piscazzi, A., Lizzi, V., Remo, A., Pancione, M., D'Andrea, M. R., Santis, E. D., Coppola, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147717 · Cited by 19
Hu, B., Patel, J. L., Tao, R., Cannon, R. B., Monroe, M. M., & Goyal, G. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7001 · Cited by 17
Colman, H. (2020) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000935 · Cited by 19
The positive clinical therapeutically effects of Escin on advanced thyroid cancer
Mei, J., Zhang, M., Wang, Y., & Liu, Y. (2017) · Cancer Medicine · doi:10.1002/cam4.1031 · Cited by 17
Péron, J., Marreaud, S. I., Staelens, D., Raveloarivahy, T., Nzokirantevye, A., Flament, J., Steuve, J., Lia, M., Collette, L., & Schöffski, P. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.12.013 · Cited by 17
Liquid Biopsy as a Minimally Invasive Source of Thyroid Cancer Genetic and Epigenetic Alterations.
Khatami, F., Larijani, B. A., Nasiri, S., & Tavangar, S. M. (2019) · PubMed Central · doi:10.22088/ijmcm.bums.8.2.19 · Cited by 17
Innovation in cancer pharmacotherapy through integrative consideration of germline and tumor genomes
Tremmel, R., Hübschmann, D., Schaeffeler, E., Pirmann, S., Fröhling, S., & Schwab, M. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.001049 · Cited by 17
Ahlborn, L. B., Tuxen, I. V., Mouliere, F. C., Kinalis, S., Schmidt, A. Y., Rohrberg, K. S., Santoni‐Rugiu, E., Nielsen, F. C., Lassen, U., Yde, C. W., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25948 · Cited by 16
Constrained hierarchical Bayesian model for latent subgroups in basket trials with two classifiers
Takeda, K., Liu, S., & Rong, A. (2021) · Statistics in Medicine · doi:10.1002/sim.9237 · Cited by 16
Defects in MMR Genes as a Seminal Example of Personalized Medicine: From Diagnosis to Therapy
Buono, A. D., Gaiani, F., Poliani, L., Correale, C., & Laghi, L. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11121333 · Cited by 16
Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
Lang, M., Longerich, T., & Anamaterou, C. (2023) · Thyroid Research · doi:10.1186/s13044-023-00147-7 · Cited by 16
Children's Oncology Group's 2023 blueprint for research: Non‐Hodgkin lymphoma
El‐Mallawany, N. K., Alexander, S. W., Fluchel, M. N., Hayashi, R. J., Lowe, E. J., Giulino-Roth, L. G., Wistinghausen, B., Hermiston, M. L., & Allen, C. E. (2023) · Pediatric Blood & Cancer · doi:10.1002/pbc.30565 · Cited by 16
Bayesian Methods for Information Borrowing in Basket Trials: An Overview
Zhou, T., & Ji, Y. (2024) · Cancers · doi:10.3390/cancers16020251 · Cited by 16
Emerging Therapies in Management of Cholangiocarcinoma
Speckart, J., Rasmusen, V., Talib, Z. M., Gnanadev, D. A., & Rahnemai‐Azar, A. A. (2024) · Cancers · doi:10.3390/cancers16030613 · Cited by 16
BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?
Caparica, R., de Castro, G., Bazo, I. G., Caglevic, C., Calogero, R., Giallombardo, M., Santos, E. S., Raez, L. E., & Rolfo, C. D. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.02.012 · Cited by 16
Clinical Trials in the Genomic Era
Joffe, E., Iasonos, A. E., & Younes, A. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.8891 · Cited by 16
Carcinoma of Unknown Primary withEML4-ALKFusion Response toALKInhibitors
Zhao, P., Peng, L., Wu, W., Zheng, Y., Jiang, W., Zhang, H., Tong, Z., Liu, L., Ma, R., Wang, L., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0439 · Cited by 16
Allen, A. N., Qin, A. C. R., Raj, N. P., Wang, J., Uddin, S., Yao, Z., Tang, L. H., Meyers, P. A., Taylor, B. S., Berger, M. F., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217399 · Cited by 16
Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy
Román, M. S., Pozas, J., Molina‐Cerrillo, J., Gómez, J., Pian, H. G., Pozas, M., Carrato, A., Grande, E., & Alonso‐Gordoa, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144951 · Cited by 17
Trullas, A., Delgado, J., Koenig, J., Fuerstenau, U., Dedorath, J., Hausmann, S., Stock, T., Enzmann, H. G., & Pignatti, F. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100031 · Cited by 16
Vemurafenib in the Treatment of Erdheim Chester Disease: A Systematic Review
Aziz, S. N., Proano, L., Cruz, C., Tenemaza, M. G., Monteros, G., Hassen, G., Baskar, A., Argudo, J. M., Duenas, J. B., & Fabara, S. P. (2022) · Cureus · doi:10.7759/cureus.25935 · Cited by 16
Precision Oncology: 2022 in Review
Rosen, E. Y., Drilon, A. E. D. C., & Chakravarty, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1154 · Cited by 16
Aly, A. A., Alshammari, M. B., Ahmad, A., Gomaa, H. A. M., Youssif, B. G. M., Bräse, S., Ibrahim, M. A. A., & Mohamed, A. H. (2023) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2023.104612 · Cited by 16
Zhang, P., Tao, C., Shimura, T., Huang, A. C., Kong, N., Dai, Y., Yao, S., Xi, Y., Wang, X., Fang, J., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107272 · Cited by 17
Emerging molecular target antagonists for the treatment of biliary tract cancer
Lombardi, P., Marino, D., Fenocchio, E., Chilà, G., Aglietta, M., & Leone, F. (2018) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2018.1444749 · Cited by 16
Low, S., & Nakamura, Y. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz073 · Cited by 16
A nonparametric Bayesian basket trial design
Xu, Y., Müller, P., Tsimberidou, A. M., & Berry, D. A. (2018) · Biometrical Journal · doi:10.1002/bimj.201700162 · Cited by 16
Blood-Based Detection of BRAF V600E in Gliomas and Brain Tumor Metastasis
Kang, K. M., Muralidharan, K., Yekula, A., Small, J. L., Rosh, Z. S., Jones, P. S., Carter, B. S., & Balaj, L. (2021) · Cancers · doi:10.3390/cancers13061227 · Cited by 16
Schmutz, M., Sommer, S., Sander, J., Graumann, D., Raffler, J., Soto‐Rey, I., Sheikhalishahi, S., Schmidt, L., Unkelbach, L. P., Ortak, L., et al. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf293 · Cited by 15
Targeting the Ras pathway in pediatric hematologic malignancies
Pikman, Y., & Stieglitz, E. (2020) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000981 · Cited by 15
Novel Study Designs in Precision Medicine – Basket, Umbrella and Platform Trials
Kesari, H. V., & Ravi, R. (2021) · Current Clinical Pharmacology · doi:10.2174/1574884716666210316114157 · Cited by 15
Lin, F. P. Y., Thavaneswaran, S., Grady, J. P., Ballinger, M. L., Kansara, M., Oakes, S. R., Desai, J., Lee, C. K., Simes, R. J., & Thomas, D. M. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00194-z · Cited by 15
Lima, B., Abreu, M. H., de Sousa, S. G., Bartosch, C., & Pereira, D. (2022) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2022.100942 · Cited by 15
Strategic Insight into the Combination Therapies for Metastatic Colorectal Cancer
Kano, Y., Suenaga, M., & Uetake, H. (2023) · Current Oncology · doi:10.3390/curroncol30070480 · Cited by 18
Tumor-Specific Activity of Precision Medicines in the NCI-MATCH Trial
Zhou, I., Plana, D., & Palmer, A. C. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0983 · Cited by 15
Histiocytose à cellules de Langerhans de l’adulte
de Menthon, M., Meignin, V., Mahr, A., & Tazi, A. (2016) · La Presse Médicale · doi:10.1016/j.lpm.2016.09.015 · Cited by 15
Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy
Kasper, S., Reis, H., Ziegler, S., Nothdurft, S., Mueller, A. M., Goetz, M., Wiesweg, M., Phasue, J., Ting, S. C., Wieczorek, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17438 · Cited by 16
Novel treatment options for anaplastic thyroid cancer
Fallahi, P., Ruffilli, I., Elia, G., Ragusa, F., Ulisse, S., Baldini, E., Miccoli, M., Materazzi, G., Antonelli, A., & Ferrari, S. M. (2017) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2017.1340155 · Cited by 15
Pool, M., de Boer, H. R., Hooge, M. N. L., van Vugt, M. A. T. M., & de Vries, E. G. E. (2017) · Theranostics · doi:10.7150/thno.17934 · Cited by 15
Ziogas, D. E., Kyrochristos, I. D., & Roukos, D. H. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.07.008 · Cited by 15
Hobbs, B. P., Kane, M. J., Hong, D. S., & Landin, R. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy457 · Cited by 15
Metadata
- Authors
- Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., Gervais, R., Elez-Fernandez, M. E., Italiano, A., Hofheinz, R.-D., Hidalgo, M., Chan, E., Schuler, M., Lasserre, S. F., Makrutzki, M., Sirzen, F., Veronese, M. L., Tabernero, J., & Baselga, J.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- From Memorial Sloan Kettering Cancer Center, New York (D.M.H., E.L.D., J.B.); Vanderbilt University Medical Center, Nashville (I.P., E.C.); University of Texas M.D. Anderson Cancer Center, Houston (V.S.); Massachusetts General Hospital, Boston (J.E.F., N.S.R.); Royal Marsden Hospital, Sutton, Surrey, United Kingdom (I.C.); Centre Léon Bérard, Lyon (J.-Y.B.), Institut Gustave Roussy, Villejuif (A.H.), Centre François Baclesse, Centre Hospitalier Universitaire Côte de Nacre, Caen (R.G.), and Institut...
- F. Hoffmann-La Roche AG (CH)
- Universitat Autònoma de Barcelona (ES)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-08-20
- Volume
- 373
- Issue
- 8
- Pages
- 726-736
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4971773
- OpenAlex
- W1846586690
- Semantic Scholar
- abd7e5ae4940f84d6af08e479e67fa7e4788098c
- Cited by
- 1,764
- References
- 31
- Citations by year
- 2026: 55 · 2025: 102 · 2024: 115 · 2023: 122 · 2022: 143 · 2021: 189 · 2020: 210 · 2019: 192 · 2018: 192 · 2017: 241 · 2016: 169 · 2015: 30
- FWCI
- 91.52
- Type
- journal article
- Language
- en
- Update notices
- correction (2018-10-18)
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Funders
- F. Hoffmann-La Roche
- National Cancer Institute (P30CA008748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- vemurafenib, BRAF V600 mutation, basket trials, non-small cell lung cancer, Erdheim-Chester disease, Langerhans cell histiocytosis, colorectal cancer, cetuximab, pleomorphic xanthoastrocytoma, anaplastic thyroid carcinoma, cholangiocarcinoma, ovarian cancer, clear cell sarcoma, targeted therapy
- MeSH terms
- Vemurafenib, Aged, Aged, 80 and over, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Indoles, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasms, Sulfonamides, Histiocytosis, Disease-Free Survival, Proto-Oncogene Proteins B-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
